Jak kontrolować objawy nocne u pacjentów z chorobą refluksową przełyku? Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
mar 31, 2024
Słowa kluczowe:
choroba refluksowa przełyku, nocne przełamanie wydzielania kwasu, inhibitory pompy protonowej, antagoniści receptora H2
##plugins.themes.bootstrap3.article.main##
Abstrakt
U 80% pacjentów z chorobą refluksową przełyku zgaga i regurgitacje występują także w godzinach nocnych. Nocna postać GERD sprzyja rozwojowi powikłań, takich jak: nadżerkowe zapalenie przełyku, owrzodzenia, zwężenie przełyku, przełyk Barretta i rak gruczołowy przełyku. Postępowanie terapeutyczne oprócz modyfikacji stylu życia uwzględnia farmakoterapię z wykorzystaniem inhibitorów pompy protonowej i antagonistów receptora H2.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Gąsiorowska, A. (2024). Jak kontrolować objawy nocne u pacjentów z chorobą refluksową przełyku? . Medycyna Faktów , 17(1(62), 115-118. https://doi.org/10.24292/01.MF.0124.18
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Nirvan JS, Hasan SS, Babar ZUD et al. Global prevalence and risk factors of gastro-oesophageal reflux disease (GORD): systematic review with meta-analysis. Sci Rep. 2020; 10: 5814.
2. Ziółkowski BA, Pacholec A, Kudlicka M et al. Epidemiologia dolegliwości brzusznych w polskiej populacji. Prz Gastroenterol. 2012; 7(1): 20-5.
3. Gyawali CP, Yadlapati R, Fass R et al. Update to the modern diagnosis of GERD: the Lyon Consensus 2.0. Gut. 2024; 73: 361-71.
4. Shaker R, Castell DO, Schoenfeld PS et al. Nighttime heartburn is an under-appreciated clinical problem that impacts sleep and daytime function: the results of a Gallup survey conducted on behalf of the American Gastroenterological Association. Am J Gastroenterol. 2003; 98(7): 1487-93.
5. Gerson LB, Fass R. A systematic review of the definitions, prevalence, and response to treatment of nocturnal gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2009; 7(4): 372-8.
6. Shibli F, Skeans J, Yamasaki T et al. Nocturnal gastroesophageal reflux disease (GERD) and sleep an important relationship that is commonly overlooked. J Clin Gastroenterol. 2020; 54: 663-74.
7. Orr WC. Sleep and gastroesophageal reflux: what are the risks? Am J Med. 2003; 115(suppl 3A): 109-13.
8. Bredenoord AJ, Hemmink GJ, Smout AJ. Relationship between gastro-oesophageal reflux pattern and severity of mucosal damage. Neurogastroenterol Motil. 2009; 21(8): 807-12.
9. Lim KG, Morgenthaler TI, Katzka DA. Sleep and nocturnal gastroesophageal reflux. An update. Chest. 2018; 154(4): 963-71.
10. Schuitenmaker JM, Kuipers T, Smout AJPM et al. Systematic review: Clinical effectiveness of interventions for the treatment of nocturnal gastroesophageal reflux. Neurogastroenterol Motil. 2022; 34: e14385.
11. Świdnicka‑Siergiejko A, Marek T, Waśko‑Czopnik D et al. Postępowanie diagnostyczno‑terapeutyczne w chorobie refluksowej przełyku. Konsensus\ Polskiego Towarzystwa Gastroenterologii 2022. Med Prakt. 2022; 6: 38-74.
12. Peghini PL, Katz PO, Bracy NA et al. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol. 1998; 93: 763-7.
13. Katz PO, Anderson C, Khoury R et al. Gastro-oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors. Aliment Pharmacol Ther. 1998; 12: 1231-4.
14. Adachi K, Komazawa Y, Fuishiro H et al. Nocturnal gastric acid breakthrough during the administration of rabeprazole and ranitidine in Helicobacter pylori-negative subjects: effects of different regimens. J Gastroenterol. 2003; 38: 830-5.
15. Fackler WK, Ours TM, Vaezi MF et al. Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology. 2002; 122: 625-32.
16. Tutuian R, Katz PO, Castell DO. Nocturnal acid breakthrough: pH, drugs and bugs. Eur J Gastroenterol Hepatol. 2004, 16: 441-3.
17. Ours TM, Fackler WK, Richter JE et al. Nocturnal acid breakthrough: clinical significance and correlation with esophageal acid exposure. Am J Gastroenterol. 2003; 98: 545-50.
18. Xue S, Katz PO, Banerjee P et al. Bedtime H2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors. Aliment Pharmacol Ther. 2001; 15: 1351-6.
19. Nwokolo CU, Smith JT, Gavey C et al. Tolerance during 29 days of conventional dosing with cimetidine, nizatidine, famotidine or ranitidine. Aliment Pharmacol Ther. 1990; 4(suppl 1): 29-45.
20. Wang Y, Pan T, Wang Q et al. Additional bedtime H2-receptor antagonist for the control of nocturnal gastric acid breakthrough (Review). Cochrane Database Syst Rev. 2009; (4): CD004275.
2. Ziółkowski BA, Pacholec A, Kudlicka M et al. Epidemiologia dolegliwości brzusznych w polskiej populacji. Prz Gastroenterol. 2012; 7(1): 20-5.
3. Gyawali CP, Yadlapati R, Fass R et al. Update to the modern diagnosis of GERD: the Lyon Consensus 2.0. Gut. 2024; 73: 361-71.
4. Shaker R, Castell DO, Schoenfeld PS et al. Nighttime heartburn is an under-appreciated clinical problem that impacts sleep and daytime function: the results of a Gallup survey conducted on behalf of the American Gastroenterological Association. Am J Gastroenterol. 2003; 98(7): 1487-93.
5. Gerson LB, Fass R. A systematic review of the definitions, prevalence, and response to treatment of nocturnal gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2009; 7(4): 372-8.
6. Shibli F, Skeans J, Yamasaki T et al. Nocturnal gastroesophageal reflux disease (GERD) and sleep an important relationship that is commonly overlooked. J Clin Gastroenterol. 2020; 54: 663-74.
7. Orr WC. Sleep and gastroesophageal reflux: what are the risks? Am J Med. 2003; 115(suppl 3A): 109-13.
8. Bredenoord AJ, Hemmink GJ, Smout AJ. Relationship between gastro-oesophageal reflux pattern and severity of mucosal damage. Neurogastroenterol Motil. 2009; 21(8): 807-12.
9. Lim KG, Morgenthaler TI, Katzka DA. Sleep and nocturnal gastroesophageal reflux. An update. Chest. 2018; 154(4): 963-71.
10. Schuitenmaker JM, Kuipers T, Smout AJPM et al. Systematic review: Clinical effectiveness of interventions for the treatment of nocturnal gastroesophageal reflux. Neurogastroenterol Motil. 2022; 34: e14385.
11. Świdnicka‑Siergiejko A, Marek T, Waśko‑Czopnik D et al. Postępowanie diagnostyczno‑terapeutyczne w chorobie refluksowej przełyku. Konsensus\ Polskiego Towarzystwa Gastroenterologii 2022. Med Prakt. 2022; 6: 38-74.
12. Peghini PL, Katz PO, Bracy NA et al. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol. 1998; 93: 763-7.
13. Katz PO, Anderson C, Khoury R et al. Gastro-oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors. Aliment Pharmacol Ther. 1998; 12: 1231-4.
14. Adachi K, Komazawa Y, Fuishiro H et al. Nocturnal gastric acid breakthrough during the administration of rabeprazole and ranitidine in Helicobacter pylori-negative subjects: effects of different regimens. J Gastroenterol. 2003; 38: 830-5.
15. Fackler WK, Ours TM, Vaezi MF et al. Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology. 2002; 122: 625-32.
16. Tutuian R, Katz PO, Castell DO. Nocturnal acid breakthrough: pH, drugs and bugs. Eur J Gastroenterol Hepatol. 2004, 16: 441-3.
17. Ours TM, Fackler WK, Richter JE et al. Nocturnal acid breakthrough: clinical significance and correlation with esophageal acid exposure. Am J Gastroenterol. 2003; 98: 545-50.
18. Xue S, Katz PO, Banerjee P et al. Bedtime H2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors. Aliment Pharmacol Ther. 2001; 15: 1351-6.
19. Nwokolo CU, Smith JT, Gavey C et al. Tolerance during 29 days of conventional dosing with cimetidine, nizatidine, famotidine or ranitidine. Aliment Pharmacol Ther. 1990; 4(suppl 1): 29-45.
20. Wang Y, Pan T, Wang Q et al. Additional bedtime H2-receptor antagonist for the control of nocturnal gastric acid breakthrough (Review). Cochrane Database Syst Rev. 2009; (4): CD004275.